Citations

Mayo Clinic

Showing 10 of 108585 citations.

Treatment of IgA Nephropathy: A Rapidly Evolving Field
Karoui, Khalil El , Fervenza, Fernando C. , Vriese, An S. De , De Vriese, An S , Fervenza, Fernando C

Journal of the American Society of Nephrology | September 29, 2023 | Volume: 35 | Issue: 1 | Pages: 103-116

10.1681/asn.0000000000000242 | PMID 37772889 Get It

The pivotal event in the pathophysiology of IgA nephropathy is the binding of circulating IgA-containing immune complexes to mesangial cells, with secondary glomerular and tubulointerstitial inflammation and fibrosis. The paramount difficulty in the management of IgA nephropathy is the heterogeneity in its clinical presentation and prognosis, requiring an individualized treatment approach. Goal-directed supportive care remains the bedrock of therapy for all patients, regardless of risk of progression. Sodium–glucose transporter 2 inhibitors and sparsentan should be integral to contemporary supportive care, particularly in patients with chronic kidney damage. Pending the development of reliable biomarkers, it remains a challenge to identify patients prone to progression due to active disease and most likely to derive a net benefit from immunosuppression. The use of clinical parameters, including the degree of proteinuria, the presence of persistent microscopic hematuria, and the rate of eGFR loss, combined with the mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, crescents score, is currently the best approach. Systemic glucocorticoids are indicated in high-risk patients, but the beneficial effects wane after withdrawal and come at the price of substantial treatment-associated toxicity. Therapies with direct effect on disease pathogenesis are increasingly becoming available. While targeted-release budesonide has garnered the most attention, anti–B-cell strategies and selective complement inhibition will most likely prove their added value. We propose a comprehensive approach that tackles the different targets in the pathophysiology of IgA nephropathy according to their relevance in the individual patient.
Current Knowledge on the Interaction of Human Cytomegalovirus Infection, Encoded miRNAs, and Acute Aortic Syndrome
Nappi, Francesco , Alzamil, Almothana, Singh, Sanjeet Singh Avtaar , Spadaccio, Cristiano , Bonnet, Nicolas , Avtaar Singh, Sanjeet Singh , Nappi, Francesco , Bonnet, Nicolas

Viruses | September 29, 2023 | Volume: 15 | Issue: 10 | Pages: 2027

10.3390/v15102027 | PMID 37896804 Get It

Aortic dissection is a clinicopathological entity caused by rupture of the intima, leading to a high mortality if not treated. Over time, diagnostic and investigative methods, antihypertensive therapy, and early referrals have resulted in improved outcomes according to registry data. Some data have also emerged from recent studies suggesting a link between Human Cytomegalovirus (HCMV) infection and aortic dissection. Furthermore, the use of microRNAs has also become increasingly widespread in the literature. These have been noted to play a role in aortic dissections with elevated levels noted in studies as early as 2017. This review aims to provide a broad and holistic overview of the role of miRNAs, while studying the role of HCMV infection in the context of aortic dissections. The roles of long non-coding RNAs, circular RNAs, and microRNAs are explored to identify changes in expression during aortic dissections. The use of such biomarkers may one day be translated into clinical practice to allow early detection and prognostication of outcomes and drive preventative and therapeutic options in the future.
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases
Tefferi, Ayalew , Abdelmagid, Maymona, Al‐Kali, Aref , Patnaik, Mrinal M. , Begna, Kebede H. , Gangat, Naseema , Orazi, Attilio , Chen, Dong , Reichard, Kaaren K. , Pardanani, Animesh , Patnaik, Mrinal , Begna, Kebede , Gangat, Naseema , Orazi, Attilio , Chen, Dong , Pardanani, Animesh , Hogan, William J.

American Journal of Hematology | September 29, 2023 | Volume: 99 | Issue: 1 | Pages: 21-27

10.1002/ajh.27113 | PMID 37772442 Get It

AbstractThe World Health Organization (WHO) classification system categorizes advanced systemic mastocytosis (SM‐Adv) into aggressive SM (ASM), mast cell leukemia (MCL), and SM with associated hematological neoplasm (SM‐AHN). By contrast, the International Consensus Classification (ICC) requires “immature” MC cytomorphology for the diagnosis of MCL and limits SM‐AHN to myeloid neoplasms (SM‐AMN). The current study includes 329 patients with SM‐Adv (median age 65 years, range 18–88; males 58%): WHO subcategories SM‐AHN (N = 212; 64%), ASM (N = 99; 30%), and MCL (N = 18; 6%); ICC subcategories SM‐AMN (N = 190; 64%), ASM (N = 99; 33%), and MCL (N = 9; 3%); WHO‐defined MCL with “mature” MC cytomorphology and SM‐AHN associated with lymphoid neoplasms were operationally labeled as “MCL‐mature” (N = 9) and SM‐ALN (N = 22), respectively, and distinguished from ICC‐defined MCL and SM‐AMN. Multivariable analysis that included the Mayo alliance risk factors for survival in SM (age >60 years, anemia, thrombocytopenia, increased alkaline phosphatase) revealed more accurate survival prediction with the ICC versus WHO classification order: (i) survival was significantly worse with MCL‐immature versus MCL‐mature (hazard ratio [HR] 15; p < .01), (ii) prognostic distinction between MCL and SM‐AHN/AMN was confirmed in the context of ICC (HR 9.3; p < .01) but not WHO classification order (p = .99), (iii) survival was similar between MCL‐mature and SM‐AMN (p = .18), and (iv) SM‐AMN (HR 1.7; p < .01) but not SM‐ALN (p = .37) was prognostically distinct from ASM. The current study provides evidence for the independent prognostic contribution of both the ICC system for SM‐Adv and the Mayo alliance risk factors for survival in SM.
Financial Education in U.S. Pulmonary and Critical Care Medicine Fellowship Programs
Krutsinger, Dustin C. , Olson, Emily M. , Denson, Joshua L. , Kelm, Diana J. , Chu, David , Denson, Joshua L , Adamson, Rosemary , Stewart, Nancy H.

ATS Scholar | September 29, 2023 | Volume: 4 | Issue: 3 | Pages: 302-306

10.34197/ats-scholar.2023-0005br | PMID 37795115 Get It

Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome
Satoh, Ryota , Weigand, Stephen D. , Pham, Nha Trang Thu, Ali, Farwa , Arani, Arvin , Jack, Clifford R. , Whitwell, Jennifer L. , Josephs, Keith A. , Josephs, Keith A , Jack, Clifford R , Arani, Arvin , Satoh, Ryota , Senjem, Matthew L.

Movement Disorders | September 29, 2023 | Volume: 38 | Issue: 12 | Pages: 2282-2290

10.1002/mds.29613 | PMID 37772771 Get It

AbstractBackgroundPrevious studies have shown that magnetic susceptibility is increased in several subcortical regions in progressive supranuclear palsy (PSP). However, it is still unclear how subcortical and cortical susceptibilities vary across different PSP variants, Parkinson's disease (PD), and corticobasal syndrome (CBS).ObjectiveThis study aims to clarify the susceptibility profiles in the subcortical and cortical regions in different PSP variants, PD, and CBS.MethodsSixty‐four patients, 20 PSP‐Richardson syndrome (PSP‐RS), 9 PSP‐parkinsonism (PSP‐P), 7 PSP‐progressive gait freezing, 4 PSP‐postural instability, 11 PD, and 13 CBS, and 20 cognitively normal control subjects underwent a 3‐Tesla magnetic resonance imaging scan to reconstruct quantitative susceptibility maps. Region‐of‐interest analysis was performed to obtain susceptibility in several subcortical and cortical regions. Bayesian linear mixed effect models were used to estimate susceptibility within group and differences between groups.ResultsIn the subcortical regions, patients with PSP‐RS and PSP‐P showed greater susceptibility than control subjects in the pallidum, substantia nigra, red nucleus, and cerebellar dentate (P < 0.05). Patients with PSP‐RS also showed greater susceptibility than patients with PSP‐progressive gait freezing, PD, and CBS in the red nucleus and cerebellar dentate, and patients with PSP‐P showed greater susceptibility than PD in the red nucleus. Patients with PSP‐postural instability and CBS showed greater susceptibility than control subjects in the pallidum and substantia nigra. No significant differences were observed in any cortical region.ConclusionsThe PSP variants and CBS had different patterns of magnetic susceptibility in the subcortical regions. The findings will contribute to our understanding about iron profiles and pathophysiology of PSP and may provide a potential biomarker to differentiate PSP variants, PD, and CBS. © 2023 International Parkinson and Movement Disorder Society.
Evaluating the Impact of Pharmacist Dual Verification of Anticancer Therapy in the Modern Era
Stonerock, Devon S. , Clark, Kaylee M. , Shah, Vishal , Irvine, Clayton , Draper, Evan , Soefje, Scott A. , Clark, Kaylee, Irvine, Clayton C, Soefje, Scott A , Shah, Vishal , Clark, Kaylee

Journal of Pharmacy Technology | September 29, 2023 | Volume: 39 | Issue: 6 | Pages: 281-285

10.1177/87551225231197346 | PMID 37974597 Get It

Background: Pharmacist order verification is a critical step in ensuring medication safety for patients. While the second pharmacist verification (SPV) before dispensing anticancer therapies has been a longstanding practice, its continued necessity in the context of modern electronic health systems lacks robust evidence. Objective: This study aimed to assess the frequency of interventions performed by a second pharmacist to determine the ongoing effectiveness of the SPV process. Methods: This retrospective chart review was conducted at the Mayo Clinic, encompassing all anticancer therapy orders that necessitated an SPV. The study period extended from January 1, 2019, to June 30, 2021, and included inpatient and outpatient anticancer orders. The quantification and reporting of alterations made to discrete order fields subsequent to initial pharmacist verification of clinical significance were performed, utilizing the total number of anticancer therapy orders as the denominator. Results: Approximately 300 000 anticancer therapy orders were screened for inclusion criteria and 2.6% (N = 7634) of orders were modified on the SPV. Most changes were in the categories of rate (N = 1962), order start time (N = 1219), and pharmacy communication note (N = 777). Dosing changes greater than 10% accounted for 0.03% (N = 99) of the orders, with 10 anticancer therapies responsible for more than 50% of these changes. Conclusion and relevance: This study represents the largest report on the impact of SPV in a modern era. Our results suggest the SPV may be valuable for a small proportion of chemotherapy orders but raises questions about the necessity for broad application of this practice.
Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1
Gross, Andrea M. , Watts, Nelson B. , Fisher, Michael J. , Klesse, Laura J. , Lessing, Andrés J , McManus, M. L. , Oberlander, Beverly, Rios, Jonathan J. , Sarnoff, Herb , Simpson, Brittany , Ullrich, Nicole J. , Stevenson, David A. , Fisher, Michael J , Klesse, Laura J , Lessing, Andrés J , McManus, Miranda L , Sarnoff, Herb , Simpson, Brittany N , Gross, Andrea M , Plotkin, Scott R. , Larson, A. Noelle

Clinical Trials | September 29, 2023 | Volume: 21 | Issue: 1 | Pages: 29-39

10.1177/17407745231201338 | PMID 37772407 Get It

Neurofibromatosis type 1 is a genetic syndrome characterized by a wide variety of tumor and non-tumor manifestations. Bone-related issues, such as scoliosis, tibial dysplasia, and low bone mineral density, are a significant source of morbidity for this population with limited treatment options. Some of the challenges to developing such treatments include the lack of consensus regarding the optimal methods to assess bone health in neurofibromatosis type 1 and limited data regarding the natural history of these manifestations. In this review, the Functional Committee of the Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration: (1) presents the available techniques for measuring overall bone health and metabolism in persons with neurofibromatosis type 1, (2) reviews data for use of each of these measures in the neurofibromatosis type 1 population, and (3) describes the strengths and limitations for each method as they might be used in clinical trials targeting neurofibromatosis type 1 bone manifestations. The Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration supports the development of a prospective, longitudinal natural history study focusing on the bone-related manifestations and relevant biomarkers of neurofibromatosis type 1. In addition, we suggest that the neurofibromatosis type 1 research community consider adding the less burdensome measurements of bone health as exploratory endpoints in ongoing or planned clinical trials for other neurofibromatosis type 1 manifestations to expand knowledge in the field.
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes
Bucheit, Leslie , Liao, Jiemin , Starr, Jason S. , Barata, Pedro C. , Klempner, Samuel J. , Gandara, David R. , Shergill, Ardaman , Weipert, Caroline , Pretz, Christopher R. , Hardin, Aaron , Kiedrowski, Lesli A. , Odegaard, Justin I. , Kasi, Pashtoon Murtaza , Bucheit, Leslie A , Liao, Jiemin , Starr, Jason S , Barata, Pedro , Klempner, Samuel J , Gandara, David , Madeira da Silva, Luciana , Weipert, Caroline , Hardin, Aaron , Kiedrowski, Lesli A , Zhang, Nicole J.

JCO Precision Oncology | September 28, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.23.00118 | PMID 37769226 Get It

MSI-H identified by ctDNA: prevalence across 21 advanced cancers and outcomes from >700 patients.
Gender differences in patient experience in idiopathic inflammatory myopathies: Subanalysis from the COVAD dataset
Yoshida, Akira , Kim, Minchul , Kuwana, Masataka , Ravichandran, Naveen, Kardeş, Sinan , Milchert, Marcin , Salim, Babur , Velikova, Tsvetelina , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Ziadé, Nelly , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Singh, Yogesh Preet , Pauling, John D , Wincup, Chris , Parisi, Simone , Sainaghi, Pier Paolo , Angelis, Rossella De , Loarce‐Martos, Jesus , Gupta, Latika , Gupta, Latika , Milchert, Marcin , Agarwal, Vikas , Velikova, Tsvetelina , Parodis, Ioannis , Tan, Ai Lyn , Ziade, Nelly , Chinoy, Hector , Pauling, John D , Wincup, Chris , Yoshida, Akira , De Angelis, Rossella , Singh, Yogesh Preet , Ravichandran, Naveen, Makol, Ashima , Sen, Parikshit , Lilleker, James B , Agarwal, Vishwesh , Day, Jessica , Joshi, Mrudula , Gheita, Tamer A. , Gracia‐Ramos, Abraham Edgar , Chatterjee, Tulika , Nune, Arvind , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Knitza, Johannes , Distler, Oliver , Aggarwal, Rohit

Modern Rheumatology | September 28, 2023 | Volume: 34 | Issue: 4 | Pages: 756-766

10.1093/mr/road094 | PMID 37769200 Get It

ABSTRACTObjectivesWe aimed to investigate the gender-based differences in idiopathic inflammatory myopathies (IIMs), with a particular focus on patient-reported outcomes, utilizing the data obtained through the international COVID-19 vaccination in autoimmune disease e-survey.MethodsPatient-reported outcomes including fatigue, pain, and physical function were extracted from the COVID-19 vaccination in autoimmune disease database and compared between genders, adjusting for demographics and IIM subgroups by multivariable analysis. Inclusion body myositis (IBM) was analysed separately because of the substantial differences in outcomes.ResultsA total of 1197 complete responses from patients with IIMs as of 31 August 2021 were analysed. Seventy percent were women. Women were younger (58 [48–68] vs. 69 [58–75] years old, median [interquartile range], P &lt; .001) and were more likely to suffer from autoimmune multimorbidity, defined as three or more autoimmune diseases in an individual patient (11.4% vs. 2.8%, P &lt; .001). In non-IBM IIMs, fatigue visual analogue scale scores were higher in women (5 [3–7] vs. 4 [2–6], median [interquartile range], P = .004), whereas no significant gender-based differences were noted in IBM. Multivariable analysis in non-IBM IIMs revealed that women, residence in high-income countries, overlap myositis, and autoimmune multimorbidity were independently associated with increased fatigue.ConclusionsWomen with IIMs suffer from autoimmune multimorbidity and experience increased fatigue compared to men.
Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations
Gaddh, Manila , Scott, David G. I. , Scott, David , Baumann Kreuziger, Lisa , Wysokiński, Waldemar E. , McBane, Robert D. , Casanegra, Ana I. , Kreuziger, Lisa Baumann , Houghton, Damon E.

TH Open | September 28, 2023 | Volume: 07 | Issue: 04 | Pages: e303-e308

10.1055/a-2183-5269 | PMID 38053618 Get It

Abstract Background Published data on the risk of venous thromboembolism (VTE) with coronavirus disease 2019 (COVID-19) vaccines are scarce and inconclusive, leading to an unmet need for further studies. Methods A retrospective, multicentered study of adult patients vaccinated for one of the three approved COVID-19 vaccines in the United States of America and a pre-COVID-19 cohort of patients vaccinated for influenza at two institutions: Mayo Clinic Enterprise sites and the Medical College of Wisconsin, looking at rate of VTE over 90 days. VTE was identified by applying validated natural language processing algorithms to relevant imaging studies. Kaplan–Meier curves were used to evaluate rate of VTE and Cox proportional hazard models for incident VTE after vaccinations. Sensitivity analyses were performed for age, sex, outpatient versus inpatient status, and type of COVID-19 vaccine. Results A total of 911,381 study subjects received COVID-19 vaccine (mean age: 56.8 [standard deviation, SD: 18.3] years, 55.3% females) and 442,612 received influenza vaccine (mean age: 56.5 [SD: 18.3] years, 58.7% females). VTE occurred within 90 days in 1,498 (0.11%) of the total 1,353,993 vaccinations: 882 (0.10%) in the COVID-19 and 616 (0.14%) in the influenza vaccination cohort. After adjusting for confounding variables, there was no difference in VTE event rate after COVID-19 vaccination compared with influenza vaccination (adjusted hazard ratio: 0.95 [95% confidence interval: 0.85–1.05]). No significant difference in VTE rates was observed between the two cohorts on sensitivity analyses. Conclusion In this large cohort of COVID-19-vaccinated patients, risk of VTE at 90 days was low and no different than a pre-COVID-19 cohort of influenza-vaccinated patients.